Rosen Law Firm Investigates Potential Securities Claims for TNDM Shareholders

Written by Emily J. Thompson, Senior Investment Analyst

TNDM-0.62%

Source: PRnewswire

Updated: Nov 28 2025

0mins

Source: PRnewswire

Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing misleading business information, highlighting serious concerns regarding the company's transparency.
Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release about a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting a significant decline in market confidence regarding product safety.
Class Action Preparation: The firm is preparing a class action to recover losses for investors, demonstrating a strong commitment to protecting shareholder rights and potentially attracting more affected shareholders to participate.
Legal Service Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling complex securities cases.

TNDM

$22.48+Infinity%1D

Analyst Views on TNDM

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Analyst Rating

7 Buy

10 Hold

0 Sell

Moderate Buy

Current: 22.620

Low

14.00

Averages

22.71

High

55.00

Current: 22.620

Low

14.00

Averages

22.71

High

55.00

Truist

Hold

maintain

$17 -> $24

2025-12-18

Reason

Truist

Price Target

$17 -> $24

2025-12-18

maintain

Hold

Reason

Truist raised the firm's price target on Tandem Diabetes to $24 from $17 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Canaccord

William Plovanic

Buy

maintain

$24 -> $35

2025-12-17

Reason

Canaccord

William Plovanic

Price Target

$24 -> $35

2025-12-17

maintain

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on Tandem Diabetes to $35 from $24 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

RBC Capital

Outperform

maintain

$25 -> $30

2025-12-17

Reason

RBC Capital

Price Target

$25 -> $30

2025-12-17

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Tandem Diabetes to $30 from $25 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that it continues to benefit from Mobi adoption and has the best in-class algorithm controlling its AID systems, also stating that Tandem's global addressable market is expanding, positioning it for revenue upside.

Mizuho

Anthony Petrone

Neutral

maintain

$18 -> $21

2025-12-17

Reason

Mizuho

Anthony Petrone

Price Target

$18 -> $21

2025-12-17

maintain

Neutral

Reason

Mizuho analyst Anthony Petrone raised the firm's price target on Tandem Diabetes to $21 from $18 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.

About TNDM

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.